Due: October 28, 2024
The Defense Threat Reduction Agency (DTRA), in its role as the Joint Science and Technology Office (JSTO), seeks to establish an improved drug discovery and development platform that has the capabilities and efficiency to deliver fast and effective MCMs against biothreats and/or pathogens of military concern. Currently, the drug discovery, design, and development process have components of computational capabilities, often focused on traditional novel one-drug, one-target-oriented approaches, but fails to measure the comprehensive response of intact biological systems to drug or chemical compound exposure. For this RPP, the Department of Defense (DoD) is focused on a MCM pipeline, therapeutic development, and a drug manufacturing process that uses large-scale chemogenomic data, functional genome-wide analysis, computational methods, Machine Learning (ML)/Artificial Intelligence (AI) approaches, and other advanced drug discovery and development techniques to achieve the desired outcomes of biodefense.
Responding to this opportunity requires membership in the Medical CBRN Defense Consortium. This Consortium releases numerous solicitations throughout the year, so even if this opportunity may not end up being right for you, we strongly encourage you to join, so you are ready for the next opportunity.
Complete the form below and a program representative will reach out to you shortly to support you through the process.